Identification and analysis of tumour-associated antigens in hepatocellular carcinoma.

Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print Cited Medium: Print ISSN: 0007-0920 (Print) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.

Antigens, Neoplasm/*analysis ; Antigens, Neoplasm/*genetics ; Carcinoma, Hepatocellular/*genetics ; Liver Neoplasms/*genetics; DNA, Complementary/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; RNA, Messenger/genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Transcription, Genetic

To identify tumour and tumour-associated antigens in patients with hepatocellular carcinoma (HCC) one may find potential diagnostic markers and immunotherapeutic targets. In the current study, 30 distinct antigens reactive with serum IgG from HCC patients were identified by serological analysis of cDNA expression libraries (SEREX). The mRNA expression patterns of 14 of these 30 antigens were altered in cancer as further revealed by cDNA microarray, with upregulation for nine and downregulation for five antigens. One of the upregulated antigens was cancer-testis (CT) antigen (CAGE), which had been previously reported to be expressed exclusively in normal gametogenic tissues and aberrantly expressed in a variety of cancer cells. In our study, CAGE mRNA was expressed in 39.4% of HCC patients, 73.3% of patients with gastric cancer and 30.8% of patients with colorectal cancer. Antibodies against CAGE protein were detected in approximately 5.1% of the sera from HCC patients, 8.3% of that from gastric cancer patients and 7.3% of that from colorectal cancer patients. The relative high incidence of CAGE in cancer cells makes it a potential target for vaccine design. Another antigen of great interest is transgelin 2. The overexpression of transgelin 2 mRNA in a large per cent (69%) of HCC points to its potential as a diagnostic marker for HCC.

Clin Cancer Res. 2004 Oct 15;10(20):6946-55. (PMID: 15501973)
Cancer Res. 1999 Oct 1;59(19):4990-6. (PMID: 10519413)
Int J Cancer. 1998 May 29;76(5):652-8. (PMID: 9610721)
Glycoconj J. 2004;20(4):247-55. (PMID: 15115909)
Cancer Immunol Immunother. 2003 Mar;52(3):155-61. (PMID: 12649744)
Int J Cancer. 2004 Oct 20;112(1):51-60. (PMID: 15305375)
J Immunol. 2002 Jul 15;169(2):1102-9. (PMID: 12097419)
Cancer. 2003 May 15;97(10):2474-9. (PMID: 12733146)
Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12198-203. (PMID: 11027314)
J Biol Chem. 2000 May 19;275(20):15157-65. (PMID: 10748218)
Mol Cell Biol. 2001 Dec;21(24):8357-64. (PMID: 11713272)
Nucleic Acids Res. 2003 Dec 15;31(24):e154. (PMID: 14654707)
Immunol Rev. 2002 Oct;188:22-32. (PMID: 12445278)
J Korean Med Sci. 2003 Aug;18(4):505-9. (PMID: 12923326)
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702. (PMID: 15252201)
Cancer Immun. 2004 Nov 17;4:13. (PMID: 15546177)
Biochem Cell Biol. 2004 Apr;82(2):321-7. (PMID: 15060627)
Oncogene. 2004 Jul 1;23(30):5193-202. (PMID: 15122328)
Anal Biochem. 2000 Oct 15;285(2):194-204. (PMID: 11017702)
J Biol Chem. 2002 Mar 22;277(12):9790-9. (PMID: 11773051)
Clin Cancer Res. 2004 Mar 1;10(5):1574-9. (PMID: 15014006)
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7. (PMID: 10430922)
Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):285-90. (PMID: 10750667)
Annu Rev Biochem. 1996;65:801-47. (PMID: 8811196)
Exp Dermatol. 2004 Jan;13(1):27-32. (PMID: 15009113)
Int J Cancer. 2004 Dec 20;112(6):1042-8. (PMID: 15316942)
Biochem Biophys Res Commun. 2002 Apr 5;292(3):715-26. (PMID: 11922625)
Biochem Biophys Res Commun. 2004 Mar 19;315(4):950-8. (PMID: 14985104)
Glycoconj J. 2004;19(7-9):557-63. (PMID: 14758080)
Oncogene. 2000 Apr 27;19(18):2186-93. (PMID: 10822368)
Science. 1991 Dec 13;254(5038):1643-7. (PMID: 1840703)
Expert Opin Biol Ther. 2002 Feb;2(2):123-33. (PMID: 11849113)
Biochem Biophys Res Commun. 2003 Jul 18;307(1):52-63. (PMID: 12849980)
Exp Cell Res. 2004 Nov 1;300(2):379-87. (PMID: 15475002)
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5902-8. (PMID: 14676113)
Gastroenterology. 2004 Nov;127(5 Suppl 1):S232-41. (PMID: 15508089)
Cancer. 2002 Sep 15;95(6):1387-95. (PMID: 12216108)
J Cell Physiol. 2000 Jul;184(1):1-16. (PMID: 10825229)
Cancer Res. 2002 Jul 15;62(14):4041-7. (PMID: 12124339)
J Immunol. 2000 Jun 1;164(11):6075-81. (PMID: 10820293)
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9363-8. (PMID: 15197261)
Cancer Cell. 2004 May;5(5):455-63. (PMID: 15144953)
J Cancer Res Clin Oncol. 2004 Nov;130(11):636-44. (PMID: 15490234)

0 (Antigens, Neoplasm)
0 (DNA, Complementary)
0 (RNA, Messenger)

Date Created: 20050310 Date Completed: 20050421 Latest Revision: 20220216

20221213

PMC2361901

10.1038/sj.bjc.6602460

15756260